Adaptimmune Therapeutics PLC
ADAPY- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001621227
No open-market purchases or sales by Adaptimmune Therapeutics PLC insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Holders of 5% or more of ADAPY
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Adaptimmune Therapeutics PLC, largest stake first. The change is against the holder's previous filing.
No holder currently reports owning 5% or more of Adaptimmune Therapeutics PLC on Schedule 13D or 13G.
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
31 Schedule 13D and 13G filings on Adaptimmune Therapeutics PLC, newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Feb 17, 20268:54 AM ET | Long Focus Capital Management, LLCand 1 other | 13G | 0.00%0 shares | −8.00 ppfrom 8.00%Below 5% | Dec 31, 2025 | SEC |
| Nov 14, 202511:42 AM ET | Two Seas Capital LPand 2 others | 13G/A | 0.00%0 shares | −8.50 ppfrom 8.50%Below 5% | Sep 30, 2025 | SEC |
| Aug 19, 20256:53 PM ET | New Enterprise Associates 14, L.P.and 10 others | 13D/A | 0.00%4 shares | –Below 5% | Aug 15, 2025 | SEC |
| Aug 19, 20256:32 PM ET | EcoR1 Capital, LLCand 2 others | 13G/A | 4.20%66.0M shares | –Below 5% | Aug 15, 2025 | SEC |
| Aug 13, 20255:43 PM ET | Two Seas Capital LPand 2 others | 13G/A | 8.50%135.5M shares | +0.50 ppfrom 8.00% | Jun 30, 2025 | SEC |
| May 15, 20259:00 AM ET | Two Seas Capital LPand 2 others | 13G/A | 8.00%123.2M shares | +2.20 ppfrom 5.80% | Mar 31, 2025 | SEC |
| Feb 14, 20259:31 AM ET | Two Seas Capital LPand 2 others | 13G | 5.80%89.0M shares | New | Dec 31, 2024 | SEC |
| Feb 12, 202510:25 AM ET | Baillie Gifford & Co | 13G/A | 4.60%70.9M shares | –Below 5% | Dec 31, 2024 | SEC |
| Feb 11, 20254:40 PM ET | Long Focus Capital Management, LLCand 4 others | 13G/A | 8.00%20.5M shares | – | Dec 31, 2024 | SEC |
| Jan 8, 202510:30 AM ET | Matrix Capital Management Company, LPand 1 other | 13G/A | 0.00%0 shares | −8.80 ppfrom 8.80%Below 5% | Dec 31, 2024 | SEC |
| Dec 5, 20245:17 PM ET | Matrix Capital Management Company, LPand 1 other | 13G/A | 8.80%135.0M shares | – | Nov 30, 2024 | SEC |
| Nov 13, 2024 | Matrix Capital Management Company, LP | 13G/AOld format | – | – | – | SEC |
| Apr 2, 2024 | New Enterprise Associates 14, L.P. | 13D/AOld format | – | – | – | SEC |
| Mar 26, 2024 | EcoR1 Capital, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2024 | Baker Bros. Advisors LP | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2024 | Long Focus Capital Management, LLC | 13G/AOld format | – | – | – | SEC |
| Jan 30, 2024 | EcoR1 Capital, LLC | 13GOld format | – | New | – | SEC |
| Jan 29, 2024 | Baillie Gifford & Co | 13G/AOld format | – | – | – | SEC |
| Nov 8, 2023 | Long Focus Capital Management, LLC | 13GOld format | – | New | – | SEC |
| Jul 10, 2023 | Matrix Capital Management Company, LP | 13G/AOld format | – | – | – | SEC |
| Mar 30, 2023 | New Enterprise Associates 14, L.P. | 13D/AOld format | – | – | – | SEC |
| Feb 14, 2023 | PFM Health Sciences, LP | 13G/AOld format | – | – | – | SEC |
| Feb 13, 2023 | Capital World Investors | 13G/AOld format | – | – | – | SEC |
| Jan 18, 2023 | Baillie Gifford & Co | 13G/AOld format | – | – | – | SEC |
| Dec 2, 2022 | Baillie Gifford & Co | 13G/AOld format | – | – | – | SEC |
| May 9, 2022 | PFM Health Sciences, LP | 13GOld format | – | New | – | SEC |
| Jan 18, 2022 | Baillie Gifford & Co | 13G/AOld format | – | – | – | SEC |
| Feb 16, 2021 | Capital World Investors | 13GOld format | – | New | – | SEC |
| Feb 16, 2021 | Baker Bros. Advisors LP | 13GOld format | – | New | – | SEC |
| Feb 16, 2021 | Matrix Capital Management Company, LP | 13G/AOld format | – | – | – | SEC |
| Jan 28, 2021 | Baillie Gifford & Co | 13GOld format | – | New | – | SEC |
Form 144: proposed insider sales
13 notices from officers, directors and other affiliates planning to sell Adaptimmune Therapeutics PLC shares, newest first.
| Filed (ET) | Seller | Shares to sell | Market value | Planned sale | Broker | Filing |
|---|---|---|---|---|---|---|
| Sep 2, 20258:00 AM ET | Gavin WoodChief Financial Officer | 16.0K | $942.4 | Sep 2, 2025 | Rowan Dartington | SEC |
| Aug 29, 20256:24 PM ET | William BertrandChief Operating Officer | 34.5K | $2.07K | Aug 28, 2025 | ETrade by Morgan Stanley | SEC |
| Aug 15, 20254:24 PM ET | New Enterprise Associates, 14 LPAffiliate | 13.8M | $981.9K | Aug 15, 2025 | J.P. Morgan Securities LLC | SEC |
| Aug 15, 20254:23 PM ET | New Enterprise Associates, 16 LPAffiliate | 3.25M | $230.8K | Aug 15, 2025 | J.P. Morgan Securities LLC | SEC |
| Jan 17, 20253:07 PM ET | Norry ElliotChief Medical Officer | 5.58K | $3.24K | Jan 17, 2025 | Maxim Group | SEC |
| Jan 17, 20252:59 PM ET | Lunger JohnChief Patient Supply Officer | 5.58K | $3.24K | Jan 17, 2025 | Maxim Group | SEC |
| Jan 17, 20252:50 PM ET | Bertrand William C JRChief Operating Officer | 5.58K | $3.24K | Jan 17, 2025 | Maxim Group | SEC |
| Jan 17, 20252:42 PM ET | Rawcliffe AdrianChief Executive Officer | 30.6K | $17.8K | Jan 17, 2025 | Maxim Group | SEC |
| Jan 15, 20254:01 PM ET | Bertrand William C JRChief Operating Officer | 19.5K | $11.4K | Jan 13, 2025 | Maxim Group | SEC |
| Jan 15, 20253:55 PM ET | Piccina CintiaChief Commercial Officer | 13.0K | $7.47K | Jan 15, 2025 | Maxim Group | SEC |
| Jan 15, 20253:50 PM ET | Norry ElliotChief Medical Officer | 22.2K | $12.9K | Jan 13, 2025 | Maxim Group | SEC |
| Jan 15, 20253:43 PM ET | Lunger JohnChief Patient Supply Officer | 19.5K | $11.4K | Jan 13, 2025 | Maxim Group | SEC |
| Jan 15, 20253:34 PM ET | Rawcliffe AdrianChief Executive Officer | 59.6K | $34.6K | Jan 13, 2025 | MAXIM GROUP | SEC |